| ANXA1 |
Low: renal cancer Fu et al. (2020)
|
High: HER2+ BC; ESCC Paweletz et al. (2000)
Low: HNSCC Garcia Pedrero et al. (2004)
|
Low, HNSCC differentiation grading, detection of epithelial dysplasia Garcia Pedrero et al. (2004); low, OSCC blood biomarker Faria et al. (2010)
|
ESCC Han et al. (2018); multiple myeloma Jia et al. (2018); NPC Huang et al. (2016)
|
Ac 2-26 Cardin et al. (2019); Guan et al. (2019)
|
| High: OC Fu et al. (2020)
|
| ANXA2 |
High: osteosarcoma Gillette et al. (2004)
|
High: ESCC Ma et al. (2014); NPC Chen et al. (2015); NSLC; HCC; OC; BC Li et al. (2021b)
Low: HNSCC Rodrigo et al., 2011b. (2014), sinonasal adenocarcinoma Rodrigo et al. (2011a)
|
|
NPC Chen et al. (2015); BC Madureira et al. (2012); Grindheim et al. (2016)
|
CLG-shANXA2 Andey et al. (2014); anti-ANXA2 antibodies Lokman et al. (2013); ANXA2-targeting peptide motif CBP12 Staquicini et al. (2017), Lm-ANXA2 Kim et al. (2019)
|
| ANXA3 |
|
High: GC; HCC; BC Liu et al. (2021a)
|
Prostate cancer Schostak et al. (2009)
|
HCC; OC; lung cancer; prostate cancer; BC; CRC Liu et al. (2021a)
|
|
| ANXA4 |
|
High: OSCC Liu et al. (2016a); OC Choi et al. (2013)
|
OSCC lepcha et al. (2021)
|
MESO Yamashita et al. (2012); NSCLC Gaudio et al. (2016); Zheng et al. (2018); Scala et al. (2021); OSCC Xiong et al. (2011); OC Morimoto et al. (2014) |
|
| ANXA5 |
Positive: adult AML Niu et al. (2019)
|
High: glioma Zhong et al. (2021); HCC Sun et al. (2018); bladder Wu et al. (2021); CRC Xue et al. (2009); CSCC Shapanis et al. (2021)
|
|
NPC (Tang et al., 2012) |
|
| ANXA6 |
|
Low: CC Sun et al. (2020); basal-like BC* Koumangoye et al. (2013)
High: PDA Leca et al. (2016)
|
CC (Lomnytska et al., 2010); esophageal adenocarcinoma (Zaidi et al., 2014); HCC (Meier et al., 2016); OC (Noreen et al., 2020) |
TNBC Koumangoye et al. (2013); Widatalla et al. (2019); Li et al. (2021a)
|
|
| ANXA7 |
High: GBM Hung and Howng. (2003)
|
High: GC
a
Yuan et al. (2014); HCC Sun et al. (2009a); HCC Sun et al. (2009b); HER2- BC Srivastava et al. (2001a), Srivastava et al. (2004).
Low: prostate Srivastava et al. (2001a), Srivastava et al. (2004).
|
Melanoma less invasive subtypes Kataoka et al. (2000); HER2- BC Srivastava et al. (2004)
|
|
|
| ANXA8 |
|
High: GC Ma et al. (2020); pancreatic cancer Pimiento et al. (2015); OC Gou et al. (2019); Zhu et al. (2020); OSCC Oka et al. (2016)
|
ER- basal-like DCIS subgroup Rossetti et al. (2016)
|
|
|
| ANXA9 |
|
High: CRC Miyoshi et al. (2014); Yu et al. (2018); BC Xiao et al. (2019); GC Zhou et al. (2021); OC Kou et al. (2021)
|
HNSCC differentiation grading Salom et al. (2019)
|
OC Kou et al. (2021)
|
|
| ANXA10 |
|
High: LUAD Yumura et al. (2022); GBM Xu et al. (2021); OC Wang et al. (2019); PDAC Ishikawa et al. (2022b); small bowel adenocarcinoma Ishikawa et al. (2021); PTC Liu et al. (2021b); CRC Bae et al. (2015); ESCC Kodaira et al. (2019); intrahepatic cholangiocarcinoma Shao et al. (2022); melanoma Zhang et al. (2021a)
Low: early GC Ishikawa et al. (2020); bladder Munksgaard et al. (2011); HCC Liu et al. (2002), HCC Liu et al. (2012)
|
Serrated neoplasia pathway in CRC Bae et al. (2015); specific biomarker for gastrointestinal and pancreatic adenocarcinomas Lu et al. (2013); PDA Zhu et al. (2017)
|
|
|
| ANXA11 |
High: bladder Yao et al. (2022)
|
High: GC Hua et al. (2018); CRC Duncan et al. (2008); AML Song et al. (2022)
|
Bladder cancer Wu et al. (2021)
|
OC Song et al. (2007); mCRC Kim et al. (2011), Kim et al. (2013); Roh et al. (2016); AML Song et al. (2022)
|
|
| ANXA13 |
|
High: CRC Jiang et al. (2017); LUAD Xue et al. (2020)
|
|
|
|
